Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS – Get Rating) passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.08 and traded as low as $0.94. Atossa Therapeutics shares last traded at $0.95, with a volume of 276,793 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Ascendiant Capital Markets cut their price target on Atossa Therapeutics to $7.00 in a research note on Monday, August 22nd.
Atossa Therapeutics Price Performance
The company has a market capitalization of $120.29 million, a P/E ratio of -5.59 and a beta of 1.66. The stock has a 50-day moving average price of $0.99 and a 200-day moving average price of $1.08.
Hedge Funds Weigh In On Atossa Therapeutics
A number of hedge funds have recently made changes to their positions in ATOS. First Republic Investment Management Inc. increased its holdings in Atossa Therapeutics by 79.8% in the first quarter. First Republic Investment Management Inc. now owns 25,167 shares of the company’s stock worth $31,000 after purchasing an additional 11,167 shares in the last quarter. QCM Cayman Ltd. bought a new stake in Atossa Therapeutics in the fourth quarter worth approximately $36,000. ProShare Advisors LLC increased its holdings in Atossa Therapeutics by 70.5% in the fourth quarter. ProShare Advisors LLC now owns 25,560 shares of the company’s stock worth $41,000 after purchasing an additional 10,566 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Atossa Therapeutics by 144.2% in the fourth quarter. Principal Financial Group Inc. now owns 26,254 shares of the company’s stock worth $42,000 after purchasing an additional 15,501 shares in the last quarter. Finally, ETF Managers Group LLC bought a new stake in Atossa Therapeutics in the fourth quarter worth approximately $64,000. 18.47% of the stock is currently owned by institutional investors.
Atossa Therapeutics Company Profile
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
- Get a free copy of the StockNews.com research report on Atossa Therapeutics (ATOS)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn’t Differentiate, But it’s Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.